NCT03151005View on ClinicalTrials.gov

The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 1, 2017

Primary Completion Date

April 1, 2021

Study Completion Date

April 23, 2021

Conditions
Polycystic Ovary Syndrome (PCOS)OverweightObesity
Interventions
DRUG

Metformin-GLP-1 Receptor Agonist

metformin oral with exenatide/liraglutide subcutaneous injection.

DRUG

Metformin-Oral Contraceptive(OC)

metformin with Diane 35 oral intake.

Trial Locations (1)

400037

The Second Affiliated Hospital, Third Military Medical University, Chongqing

All Listed Sponsors
lead

Xinqiao Hospital of Chongqing

OTHER

NCT03151005 - The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS | Biotech Hunter | Biotech Hunter